Filtros de búsqueda

Lista de obras de

A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score

artículo científico publicado en 2017

Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation

scientific article published on 27 September 2020

Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation

scientific article published on 17 March 2019

Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine: A Secondary Analysis of a Randomized Clinical Trial

artículo científico

Apixaban versus Warfarin in Patients with Atrial Fibrillation and Advanced Chronic Kidney Disease

artículo científico publicado en 2020

Application of Biomarkers for Risk Stratification in Patients with Atrial Fibrillation

artículo científico publicado en 2016

Association of Different Estimates of Renal Function With Cardiovascular Mortality and Bleeding in Atrial Fibrillation

scientific article published on 31 August 2020

Biomarkers in atrial fibrillation: a clinical review

artículo científico

Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation

artículo científico

Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the RE - LY Trial

Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) substudy

artículo científico publicado en 2012

Cardiac troponin is associated with cardiac outcomes in men and women with atrial fibrillation, insights from the ARISTOTLE trial

scientific article published on 30 April 2020

Cardiovascular outcomes, bleeding risk, and achieved blood pressure in patients on long-term anticoagulation with the thrombin antagonist dabigatran or warfarin: data from the RE-LY trial

scientific article published on 08 May 2020

Changes in Renal Function in Patients With Atrial Fibrillation: An Analysis From the RE-LY Trial

artículo científico publicado en 2015

Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) Tria

artículo científico publicado en 2018

Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time: Insights From the ARISTOTLE Randomized Clinical Trial

artículo científico

Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight

artículo científico publicado en 2019

Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time-A RE-LY trial analysis

artículo científico publicado en 2018

Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis

artículo científico

Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial

artículo científico publicado en 2012

Evaluation of the Age, Biomarkers, and Clinical History-Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY Trials

scientific article published on 01 September 2020

Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARI

artículo científico

Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial

artículo científico publicado en 2017

High-sensitivity troponin I for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial

artículo científico publicado en 2013

High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin

artículo científico publicado en 2013

Importance of persistent elevation of cardiac biomarkers in atrial fibrillation: a RE-LY substudy

artículo científico publicado en 2014

Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation

artículo científico publicado en 2015

International normalized ratio control and subsequent clinical outcomes in patients with atrial fibrillation using warfarin

scientific article published on 01 July 2019

N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation).

artículo científico publicado en 2013

Natriuretic peptide should be used as a routine tool for evaluation of patients with atrial fibrillation

artículo científico publicado en 2018

Obesity paradox on outcome in atrial fibrillation maintained even considering the prognostic influence of biomarkers: insights from the ARISTOTLE trial

article published in 2018

Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: Insights from the ARISTOTLE trial

scientific article published on 22 November 2018

Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation

artículo científico

RISK OF STROKE IN WOMEN AND MEN WITH ATRIAL FIBRILLATION AND ONLY ONE ADDITIONAL CHA2DS2-VASC RISK FACTOR

Regional variation in clinical characteristics and outcomes in patients with atrial fibrillation: Findings from the ARISTOTLE trial

scientific article published on 30 December 2019

Renal Function in Atrial Fibrillation: A Multifaceted Dilemma

artículo científico publicado en 2016

Repeated Measurements of Cardiac Biomarkers in Atrial Fibrillation and Validation of the ABC Stroke Score Over Time

artículo científico publicado en 2017

Reply: Anticoagulant-Related Nephropathy

scientific article published on 01 December 2015

Reply: Higher N-terminal Pro-B-type natriuretic peptide may be related to very different conditions

artículo científico publicado en 2013

Response to letter regarding article, "Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a randomized evaluation of long-term anticoagulation therapy (RE-LY) substudy".

artículo científico publicado en 2013

Response to letter regarding article, "Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial a

artículo científico publicado en 2014

Risk Markers of Incident Atrial Fibrillation in Patients with Coronary Heart Disease

scientific article published on 02 January 2021

Risk of ischemic stroke and utility of CHA2 DS2 -VASc score in women and men with atrial fibrillation

artículo científico publicado en 2019

Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation

scientific article published on 09 December 2020

Serial measurement of interleukin-6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE-LY trials

artículo científico publicado en 2020

The 'obesity paradox' in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial.

artículo científico publicado en 2016

The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation

artículo científico publicado en 2016

The ABC risk score for patients with atrial fibrillation - Authors' reply.

artículo científico publicado en 2016

The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study.

artículo científico publicado en 2016

Use of Biomarkers to Predict Specific Causes of Death in Patients With Atrial Fibrillation

artículo científico publicado en 2018

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda